Actively Recruiting
Recurrent High Grade Glioma Treated by LITT
Led by Beijing Tiantan Hospital · Updated on 2024-11-29
135
Participants Needed
9
Research Sites
208 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This clinical trial aims to investigate the efficiency and safety of laser interstitial thermal therapy (LITT) in recurrent high-grade glioma (rHGG) patients. The main questions it aims to answer are: * The LITT would increase the progression-free survival and overall survival of rHGG patients compared to other treatments. * The LITT is safe and applicable to rHGG patients Participants will be randomized to the intervention group (LITT) or control group at a ratio of 2:1. The intervention group patients will receive LITT. The control group will be treated with any other treatment. The primary outcome of this trial is progression-free survival. The estimated sample size is 135, 90 in the LITT group and 45 in the control group.
CONDITIONS
Official Title
Recurrent High Grade Glioma Treated by LITT
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged 18 years old or above
- Previous pathological diagnosis of WHO CNS5 grade 3 or 4 glioma
- Meet at least one progression criteria: RANO 2.0 disease progression, imaging indicating progression, pathology showing progression or recurrence, or progression as determined by Clinical Events Committee
- All tumor lesions located supratentorial with maximum cross-sectional short-axis length ≤30 mm
- Karnofsky Performance Score (KPS) ≥ 60 and able to tolerate intervention
- Ability to understand the trial purpose, comply with protocol, and provide informed consent
You will not qualify if you...
- Patients who may benefit from other treatments or not benefit from this trial
- Craniotomy within the past 3 months
- Unable to undergo MRI contrast
- Severe coagulation disorder
- Pregnant, lactating, or planning pregnancy within 6 months
- Participation in other drug or device clinical trials within 3 months
- Presence of diseases interfering with treatment or prognosis assessment
- Refusal or inability to complete follow-up assessments
- Other conditions deemed inappropriate for participation by the researcher
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 9 locations
1
Beijing Tiantan Hospital
Beijing, Beijing Municipality, China
Actively Recruiting
2
Beijing Tsinghua Changgung Hospital
Beijing, Beijing Municipality, China
Not Yet Recruiting
3
The First Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, China
Actively Recruiting
4
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
Actively Recruiting
5
Tongji Hospital
Wuhan, Hubei, China
Actively Recruiting
6
The First Hospital of Jilin University
Changchun, Jilin, China
Actively Recruiting
7
The Peoples Hospital of Liaoning
Shenyang, Liaoning, China
Actively Recruiting
8
Qilu Hospital
Jinan, Shandong, China
Actively Recruiting
9
Huashan Hospital
Shanghai, Shanghai Municipality, China
Actively Recruiting
Research Team
Y
Yunke Li, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here